Ignite Creation Date:
2024-05-06 @ 8:44 AM
Last Modification Date:
2024-10-26 @ 12:04 PM
Study NCT ID:
NCT02813720
Status:
UNKNOWN
Last Update Posted:
2016-06-28
First Post:
2016-06-22
Brief Title:
Distal Erosions and Nail Psoriasis
Sponsor:
Hospices Civils de Lyon
Organization:
Hospices Civils de Lyon
Study Overview
Official Title:
Distal Phalangeal Bone Involvement Observed by High Resolution Peripheral Quantitative Computed Tomography HR-pQCT in Patients With Nail Psoriasis
Status:
UNKNOWN
Status Verified Date:
2016-06
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PSUPSO
Brief Summary:
Nearly 30 of patients with cutaneous psoriasis PsO developed psoriatic arthritis PsA Among these patients 20 will have severe destructive arthritis The risk of developing PsA is significantly higher in patients with nail involvement OR 224 95 CI 126-398 The risk is particularly high for the peripheral form of PsA and onycholysis OR280 95 CI 134-585
Thus the investigators wanted to test the hypothesis that onycholysis in patients without PsA is a potential clinical marker of subclinical distal enthesopathy and by extension of bone micro-structural alterations
Patients and Methods
The investigators will recruit 4 groups of subjects
1 Patients with peripheral PsA
2 Patients with psoriatic nail onycholysis
3 Patients with PsO only
4 Healthy match control subjects The investigators will assess the presence of enthesopathy by ultrasonography and bone structural damages by HR-pQCT in all subjects at baseline and 4 years
Thus the investigators wanted to test the hypothesis that onycholysis in patients without PsA is a potential clinical marker of subclinical distal enthesopathy and by extension of bone micro-structural alterations
Patients and Methods
The investigators will recruit 4 groups of subjects
1 Patients with peripheral PsA
2 Patients with psoriatic nail onycholysis
3 Patients with PsO only
4 Healthy match control subjects The investigators will assess the presence of enthesopathy by ultrasonography and bone structural damages by HR-pQCT in all subjects at baseline and 4 years
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None